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Abstract: PURPOSE Clinical stage I (CSI) nonseminoma (NS) is a disease limited to the testis without
metastases. One treatment strategy after orchiectomy is adjuvant chemotherapy. Little is known about
the outcome of patients who experience relapse after such treatment. PATIENTS AND METHODS
Data from 51 patients with CSI NS who experienced a relapse after adjuvant bleomycin, etoposide,
and cisplatin (BEP) from 18 centers/11 countries were collected and retrospectively analyzed. Primary
outcomes were overall and progression-free survivals calculated from day 1 of treatment at first relapse.
Secondary outcomes were time to, stage at, and treatment of relapse and rate of subsequent relapses.
RESULTS Median time to relapse was 13 months, with the earliest relapse 2 months after start of
adjuvant treatment and the latest after 25 years. With a median follow-up of 96 months, the 5-year
PFS was 67% (95% CI, 54% to 82%) and the 5-year OS was 81% (95% CI, 70% to 94%). Overall, 19
(37%) of 51 relapses occurred later than 2 years. Late relapses were associated with a significantly higher
risk of death from NS (hazard ratio, 1.10 per year; P = .01). Treatment upon relapse was diverse: the
majority of patients received a combination of chemotherapy and surgery. Twenty-nine percent of patients
experienced a subsequent relapse. At last follow-up, 41 patients (80%) were alive and disease-free, eight
(16%) had died of progressive disease, and one patient (2%) each had died from therapy-related or other
causes. CONCLUSION Outcomes of patients with relapse after adjuvant BEP seem better compared
with patients who experience relapse after treatment of metastatic disease but worse compared with those
who have de-novo metastatic disease. We found a substantial rate of late and subsequent relapses. There
seem to be three patterns of relapse with different outcomes: pure teratoma, early viable NS relapse (<
2 years), and late viable NS relapse (> 2 years).
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ab
stract
PURPOSE Clinical stage I (CSI) nonseminoma (NS) is a disease limited to the testis without metastases. One
treatment strategy after orchiectomy is adjuvant chemotherapy. Little is known about the outcome of patients
who experience relapse after such treatment.
PATIENTS ANDMETHODSData from 51 patients with CSI NS who experienced a relapse after adjuvant bleomycin,
etoposide, and cisplatin (BEP) from 18 centers/11 countries were collected and retrospectively analyzed.
Primary outcomes were overall and progression-free survivals calculated from day 1 of treatment at first relapse.
Secondary outcomes were time to, stage at, and treatment of relapse and rate of subsequent relapses.
RESULTS Median time to relapse was 13 months, with the earliest relapse 2 months after start of adjuvant
treatment and the latest after 25 years. With a median follow-up of 96months, the 5-year PFS was 67% (95% CI,
54% to 82%) and the 5-year OS was 81% (95% CI, 70% to 94%). Overall, 19 (37%) of 51 relapses occurred
later than 2 years. Late relapses were associated with a significantly higher risk of death from NS (hazard ratio,
1.10 per year; P = .01). Treatment upon relapse was diverse: the majority of patients received a combination of
chemotherapy and surgery. Twenty-nine percent of patients experienced a subsequent relapse. At last follow-
up, 41 patients (80%) were alive and disease-free, eight (16%) had died of progressive disease, and one patient
(2%) each had died from therapy-related or other causes.
CONCLUSION Outcomes of patients with relapse after adjuvant BEP seem better compared with patients who
experience relapse after treatment of metastatic disease but worse compared with those who have de-novo
metastatic disease. We found a substantial rate of late and subsequent relapses. There seem to be three patterns
of relapse with different outcomes: pure teratoma, early viable NS relapse (, 2 years), and late viable NS relapse
(. 2 years).
J Clin Oncol 38. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Clinical stage I (CSI) nonseminoma (NS) is defined as
disease limited to the testis without evidence of me-
tastases. After inguinal orchiectomy, there are different
management possibilities for these patients: active
surveillance, retroperitoneal lymph node dissection,
and adjuvant chemotherapy with bleomycin, etopo-
side, cisplatin (BEP).1 The risk of relapse in patients
without adjuvant treatment after orchiectomy is ap-
proximately 15% for patients without lymphovascular
invasion (LVI; low risk) and up to 50% for patients in
whom LVI is present (high risk). Adjuvant chemo-
therapy with one or two cycles of BEP reduces the
risk of relapse by approximately 90%, to about 1% to
3%.2-7 In some countries/centers, active surveillance
is the preferred management option for disease in the
majority of patients, independent of presence of LVI.8
In other countries, adjuvant chemotherapy often is
preferred in patients with high-risk, LVI-positive dis-
ease, whereas active surveillance frequently is used for
patients with low risk.1 Data about patients who ex-
perience relapse despite adjuvant chemotherapy with
BEP are rare. So far, to our knowledge, no study has
investigated the timing, location, treatment patterns,
and respective outcomes of such relapses. There is
uncertainty about whether the prognosis of patients
who experience relapse after adjuvant BEP is affected
by their previous adjuvant treatment and whether
certain characteristics predict a worse outcome. Be-
cause of the rarity of the situation, it is almost im-
possible to conduct a prospective trial in this patient
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retrospective data collection to assess disease character-
istics at time of relapse, mode of detection, treatments
given, and patient outcomes.
PATIENTS AND METHODS
Using the network of the Global Germ-Cell Cancer Group,
we contacted 30 centers worldwide to explore whether they
had treated patients with a relapse after one or two cycles of
adjuvant BEP for CSI NS. Eighteen centers had treated
such patients, but the others could not identify suitable
patient cases, underlining the rarity of this clinical situation.
Approval of the local ethics committee was obtained before
the retrospective data collection. Patient information was
collocated using predefined structured questionnaires. The
protocol and case report forms are available in the Data
Supplement (online only).
We collected data on patient characteristics at the time of
treatment with adjuvant BEP as well as initial histology, time
to, detection of, and location of relapse. In addition, data
about treatment modalities at relapse and outcome were
gathered. If applicable, data about subsequent relapses,
including treatment, were obtained, as well as cause of
death if a patient had died. Data were collected and
anonymized locally at each center and then transferred and
entered into a joint database in St Gallen, Switzerland.
Patients
Inclusion criteria were male sex, age$ 18 years, NS germ-
cell cancer (GCC) in initial histology, and CSI at initial di-
agnosis. Additional conditions for inclusion were (1)
orchiectomy for NS, (2) one or two cycles of adjuvant BEP,
and (3) clinical or radiologic confirmation of recurrent
testicular cancer.
Criteria for exclusion were (1) other malignancies requiring
cytotoxic therapy during time of follow-up, (2) pure semi-
noma histology at initial diagnosis, (3) treatment with. two
cycles of adjuvant BEP, (4) any other kind of adjuvant
chemotherapy than BEP, and (5) contralateral testicular
cancer at time of relapse—because this criterion would
have made a clear distinction impossible between me-
tastases from a contralateral cancer versus a true relapse
from the incident primary tumor.
Disease stage was reported according to the Union Inter-
nationale Contre le Cancer (UICC) classification.9 For al-
location to risk categories, the International Germ Cell
Cancer Collaborative Group (IGCCCG) prognostic classifi-
cation10 was used.
Statistical Analysis
Data of 51 patients who had received adjuvant treat-
ment with BEP between October 1987 and July 2017 and
who had experienced relapse were retrospectively ana-
lyzed. Primary outcomes were overall survival (OS) and
progression-free survival (PFS). Time to event endpoints
was analyzed by the Kaplan-Meier method. Calculation of
time to first relapse started with day 1 of adjuvant che-
motherapy. PFS and OS started with day 1 of treatment at
first relapse; PFS ended with progression of disease or
death as a result of any cause; OS endedwith death. Censoring
was done at the date of last contact. For 11 patients, the
exact date of initiation of treatment of relapse was missing.
For these patients, date of relapse plus 28 days (median
difference in patients with both dates available) was taken
as the starting date. Follow-up time was calculated with the
reverse Kaplan-Meier method, which is calculated as the
Kaplan-Meier estimate of the survival function, but death
censors the unknown observational time of an individual.
Medians and quantiles of Kaplan-Meier estimated potential
follow-ups are presented. Cox univariable models were
used to explore the prognostic value of covariables. The
proportional hazards assumption was checked, for exam-
ple by testing the scaled Schoenfeld residuals.
RESULTS
Information on 51 patients with relapse after adjuvant
treatment with BEP for CSI NS was collected and analyzed.
No patient cases needed to be excluded. The median
follow-up was 96months (interquartile range [IQR], 44-130
months). A patient flow diagram is provided in Figure 1.
Characteristics at Baseline, Mode of Detection, and Stage
at Relapse
Themedian age at orchiectomy was 30.5 years (IQR, 25-38
years), and adjuvant chemotherapy was started at a me-
dian of 40 days (min, 10 days; max, 88 days) after surgery.
Table 1 lists patient characteristics at baseline and time of
relapse.
Twenty-eight (55%) of 51 patients received two cycles of
adjuvant BEP; 23 (45%) of 51 were treated with one cycle
in the adjuvant setting. The majority of tumors had com-
ponents of embryonal carcinoma (33 [83%] of 40 patients
for whom this information was available). In approximately
two thirds of the patient cases (69%), LVI was present at
baseline.
The median time to relapse was 13 months (IQR, 9-42
months). The earliest relapse was documented 2 months
after start of adjuvant treatment, and the latest relapse was
reported after 25 years. Overall, 63% of relapses occurred
during the first 2 years; 8% were documented between year
2 and 3; and 29% of the patients experienced relapse .
3 years after adjuvant treatment. Themedian time to relapse
for patients who experienced relapse with teratoma only was
significantly shorter than for patients who experienced re-
lapse with nonteratoma (9 v 20 months; P , .001).
Most of the relapses (88%) were found in routine follow-up.
Only a minority of 12% were detected by additional visits
triggered by suspicion of relapse.
First evidence of relapse was found by imaging alone in the
majority of patient cases (46%). Approximately a quarter of
2 © 2019 by American Society of Clinical Oncology
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the relapses (28%) were detected by imaging and elevation
of tumor markers. Only a minority of patients presented with
a combination of symptoms/clinical signs and/or marker
elevation.
The majority of patients presented with stage IIB (38%) or
stage III (33%) disease at relapse. Fourteen percent had
stage IIA or IIC disease at relapse; for nine patients, stage at
relapse was unknown. Using the IGCCCG classification—
keeping in mind that it was developed for de-novo meta-
static disease—the majority of patients were classified in
the IGCCCG good prognosis group at time of relapse (84%),
12% were considered intermediate prognosis, and 4% were
considered poor prognosis.
At relapse, three patients (6%) showed histologic de-
differentiation (eg, sarcomatoid components; Data Supple-
ment) in their surgical specimens. Ten patients (20%) had
pure teratoma.
Treatments
Treatments used at first relapse are presented in Figure 2
and the Data Supplement and show a remarkable diversity.
The majority of patients received a combination of che-
motherapy and surgery. Twenty-nine percent received
chemotherapy first followed by surgery, and 16% un-
derwent primary resection followed by different regimens of
chemotherapy after vital NS had been documented (Data
Supplement). Twenty-four percent of patients received
chemotherapy alone, and 29% underwent surgery as
single-treatment modality. Two thirds of these patients who
underwent surgery alone had pure teratoma.
Surgery was performed in the retroperitoneum alone (82%)
or in the retroperitoneum as well as at other localizations,
such as lung or mediastinum (Data Supplement). Only one
patient (2%) received radiotherapy in combination with
surgery as treatment of first relapse.
Concerning primary chemotherapy, most patients received
treatment with BEP; etoposide, ifosfamide, and cisplatin; or
paclitaxel, ifosfamide, and cisplatin (Data Supplement).
Only two patients were treated with etoposide plus cisplatin,
and one patient received high-dose chemotherapy upfront
as treatment of first relapse. Of those patients receiving
chemotherapy as part of the treatment of first relapse,
according to the IGCCCG prognosis group, 16 (46%) of 35
received what would be a standard chemotherapy regimen
for de-novometastatic disease (eg, three cycles BEP or four
cycles of etoposide plus cisplatin for good prognosis or four
cycles BEP or etoposide, ifosfamide, and cisplatin for in-
termediate and poor prognosis, respectively), and 17
(49%) of the 35 patients received a more intense/salvage
regimen upfront. We observed no significant difference in
terms of outcome whether patients had received a standard
or salvage regimen (data not shown).
One patient received a combination of carboplatin and

























Patients excluded due to ineligibility
(n = 0*)
FIG 1. Patient flow diagram. (*) One patient of the cohort received chemotherapy with temozolomide and a combination of procarbazine, lomustine, and
vincristine (PCV) for progressing oligodendroglioma 5 years and 10months after his NS relapse; because his first relapse was pure teratoma and was treated
with surgery alone, because of the long GCC-free interval until initiation of chemotherapy for his second malignancy, and because none of the other patients
with pure teratoma relapses experienced a subsequent relapse, it was decided not to exclude this patient from data analysis. (†) Death from oligoden-
droglioma. (‡) Patient died of sepsis, bleeding, and respiratory insufficiency during high-dose chemotherapy with carboplatin/etoposide.
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of unknown primary. After histology review, the diagnosis
was corrected to recurrent GCC, and he went on to receive
BEP after surgery. One patient was treated with a regimen
that was less intense than the standard. All chemotherapy
treatments given to each individual patient and cumulative
cycles of cisplatin-based regimens are provided in the Data
Supplement.
Subsequent Relapses and Survival
Fifteen (29%) of 51 patients experienced a subsequent
relapse. The median time from first to subsequent relapse
was 9 months (min, 1.4 months; max, 33.5 months). Of the
patients with subsequent relapses, three had primary
progression as a response to treatment of first relapse.
None of these three patients achieved cure from their
disease. Nine of the 15 patients with subsequent relapses
died: eight died as a result of progression of NS, and one
died as a result of sepsis, bleeding, and respiratory in-
sufficiency during high-dose chemotherapy (Fig 1).
At last follow-up, 41 patients (80% of the entire study
population) were alive and disease-free. Ten patients (20%)
had died, eight (16%) as a result of progressing NS. One
patient (2%) died of another malignancy during follow-up
(oligodendroglioma), and one death (2%) was considered
treatment related.
The 5-year PFS for the total population in this study was
67% (95% CI, 54% to 82%), and the 5-year OS was 81%
(95% CI, 70% to 94%; Fig 3A). The 5-year cancer-specific
survival was 83% (95% CI, 73% to 95%).
We observed no significant difference for PFS and OS
between patients receiving one versus two cycles of
adjuvant BEP (Figs 3B and 3C). Of the patients with
pure teratoma at relapse treated with surgery alone,
none experienced a subsequent relapse, and none died
of GCC.
With 10 relapses (20%) occurring more than 5 years after
adjuvant treatment, we found a substantial rate of very late
relapses. Univariable Cox analyses for the whole study
population showed that late relapses were associated with
an increased risk for subsequent progression (PFS: hazard
ratio [HR], 1.13 per year; 95% CI, 1.05 to 1.23; P = .002)
and death (HR, 1.10; 95% CI, 1.02 to 1.18; P = .01).
Patterns of Relapse in Relation to Outcome
Considering the different treatments and outcomes be-
tween patients experiencing relapse with pure teratoma
compared with patients experiencing relapse early or late
with vital undifferentiated cancer, we performed additional
survival analyses by dividing the population in this study
into three groups: (1) pure teratoma relapses treated with
surgery alone, (2) early NS relapses , 2 years after ad-
juvant treatment, and (3) late NS relapses . 2 years after
adjuvant BEP. The rate of death as a result of NS was 0% in
group 1, 13% in group 2, and 28% in group 3 (Fig 4A). PFS
and OS for the three groups are shown in Figures 4B and
TABLE 1. Patient Characteristics at Baseline and at Relapse
Characteristic
No. /Total No. (%) of
Patients
At baseline
Total No. of patients 51
Age at diagnosis, years




Second cycle of adjuvant BEP
Yes 28 (55)
No 23 (45)
Initial histology (multiple items possible)
Embryonal carcinoma 33/40 (83)
Chorionic carcinoma 3/38 (8)









Time to relapse, months
Median (min-max) for all patients 13 (2-308)
Median for teratoma only 9
Median for nonteratoma 20*
Detection of relapse
Additional follow-up triggered by suspicion 6/50 (12)
Routine follow-up 44/50 (88)
Unknown 1
First evidence of relapse
Clinical symptoms/signs only 1/50 (2)
Imaging only 23/50 (46)
Markers only 5/50 (10)
Imaging and markers 14/50 (28)
Clinical symptoms/signs + imaging 4/50 (8)
Clinical symptoms/signs + markers 1/50 (2)
Clinical symptoms/signs + markers + imaging 2/50 (4)
Unknown 1
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4C. The single PFS/OS event for group 1 was attributed to
death as a result of oligodendroglioma. There seems to be
a distinction between the three groups in terms of OS.
However, this did not reach statistical significance.
Using relapse time as a continuous variable and including
only the non-teratoma relapses, this comparison again
reached significance, with a HR for death of 1.09 per year
(95% CI, 1.01 to 1.17; P = .03). These results suggest that
the effect observed for the whole study population is driven
not only by early, prognostically favorable teratoma relapses.
DISCUSSION
We report the first, to our knowledge, retrospective analysis
focusing exclusively on patients with CSI NS who were
treated with adjuvant BEP and who had an unequivocal
relapse. The median time to relapse in this analysis was
long, at 13 months, and approximately one third of patients
experienced relapse . 3 years after adjuvant treatment.
Comparing our results with surveillance studies, adjuvant
chemotherapy with BEP not only reduces but also seems to
postpone relapses. For example, Kollmannsberger et al11
observed a median time to relapse of only 6 months for
patients with CSI NS managed with active surveillance. A
more recent single-center surveillance study observed
a similar median time to relapse of 7 months.12 In-
terestingly, in the data we reported for relapses after ad-
juvant carboplatin treatment of CSI seminoma, the time to
relapse also seemed postponed.13
Late relapses in this study seemed to be associated with
a higher risk of death as a result of disease for the whole
study population, and there is some suggestion that this is
also true when looking at the nonteratoma relapses only.
This observation is in line with other studies14-22 that also
describe late relapses as a predictor of poor outcome.
Despite the fact that most of the relapses in our analysis
occurred in an early stage and with good prognosis fea-
tures, we documented a substantial rate of subsequent
relapses (29%). In comparison, in the aforementioned
surveillance study,11 only 6% of patients experienced sub-
sequent relapses. However, LVI was present in only 16% in
that series, which suggests a selection of favorable patient
cases.
In general, our outcome data seem to compare unfavorably
with datasets of patients with chemotherapy-naive meta-
static NS in current times. In the IGCCCG population,10
patients had a 5-year PFS of 75% and a 5-year OS of 80%
compared with a 5-year PFS of 67% and a 5-year OS of
81% in our cohort. A Spanish study23 also found better
outcomes for patients with chemotherapy-naive metastatic
NS, documenting a 3-year OS rate of 96.8% for patients
with IGCCCG good prognosis and rates of 88.6% and 72%
for intermediate and poor prognoses, respectively.
A negative selection of patients may explain the worse
outcome in this study. First, adjuvant chemotherapy usually
is given to patients who are judged to be at higher risk of
relapse. Approximately two thirds of patients in this anal-
ysis had LVI at initial diagnosis, and 83% had components
of embryonal carcinoma24 in initial histology. Second, the
TABLE 1. Patient Characteristics at Baseline and at Relapse (continued)
Characteristic














Status at last follow-up
Alive and disease free 41 (80)
Death as a result of progression 8 (16)
Death, therapy relatedb 1 (2)
Death of other causec 1 (2)
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; IGCCCG, International
Germ Cell Cancer Collaborative Group; IQR, interquartile range.
*P , .001.
aRhabdomyo- and chondrosarcomatoid components.













Surgery followed by 
chemotherapy
FIG 2. Treatment modalities used for treatment of first re-
lapse. RT, radiotherapy; (*) 67% of these patients had
teratoma-only relapses.
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focus of this study was exclusively on patients experiencing
relapse after adjuvant BEP, so we might have selected
patients with biologically more aggressive disease or who
have developed a form of chemotherapy resistance. Both
hypotheses could explain the less favorable outcome
compared with patients who had de-novo metastatic
disease. However, the outcome of patients in this study still
compares favorably to patients experiencing relapse after
prior chemotherapy for metastatic NS.25-27
This study has limitations. We have a lack of full annotation of
the interval between initial computed tomography staging
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FIG 3. Survival of patients. (A) Progression-free (PFS) and overall survival (OS) for all patients. (B) PFS in relation to number of adjuvant treatment
cycles. (C) OS in relation to number of adjuvant treatment cycles.
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out that some patients had experienced progression to
clinical stage II before the start of adjuvant BEP. Moreover,
the sample size is small, in particular for the three suggested
subgroups; also, the analysis was retrospective, andwe solely
focused on patients with a relapse after adjuvant BEP.
Therefore, we cannot comment on the general population of
patients with CSI NS the sample in this study was drawn from.
However, to our knowledge, we performed the first sys-
tematic analysis of patients experiencing relapse after
adjuvant BEP. Prospective evaluation of a larger number of
relapses is likely not possible because of the rarity of this
disease setting. Thus, this study may provide some clinical
guidance for this rare situation.
Because of the substantial rate of late and subsequent
relapses in this study, we recommend that patients and
their doctors be advised of that risk. This information should
be provided when discussing adjuvant chemotherapy with
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(n = 1 [10%])*
Alive w/o
disease
(n = 9 [90%])
Alive w/o
disease 
(n = 13 [72%])
Death of PD
(n = 5 [28%])
Status at last
follow -up
Yes                      (n = 8) 
No                     (n = 15)
Yes                        (n = 7) 






treated with surgery 
(n = 10)
Early NS relapse < 2 years
(n = 23)





(n = 19 [83%])
Death of PD
(n = 3 [13%])
Death, therapy 
related
(n = 1 [4%])
A
FIG 4. Outcome in relation to pattern of relapse. (A) Subsequent relapses and outcomes according to the three groups: teratoma-only relapse, early
nonseminoma relapse, 2 years after adjuvant treatment, and late nonseminoma relapse. 2 years after adjuvant treatment; (*) oligodendroglioma; one
teratoma relapse also occurred. 2 years after adjuvant treatment. NS, nonseminoma; PD, progressive disease; w/o, without. (B) Progression-free survival
(PFS) probability in relation to group; (†) PFS event allocated to death from oligodendroglioma. (C) Overall survival (OS) in relation to group; (‡) death from
oligodendroglioma.
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BEP, fortunately, is low, we think that an imaging-based
follow-up longer than mandated in current guidelines
should not be recommended. However, it is important that
the patients and their physicians are aware of the potential
of a late relapse when new symptoms occur, especially
because most centers finish follow-up for patients with GCC
after 5 years. One patient in this study was treated primarily
for adenocarcinoma before diagnosis was corrected to
recurrent GCC, so it is important that the differential di-
agnosis of a late relapse of NS is always considered, that
biopsies are taken, and that expert pathology review is
sought. Moreover, the potential of malignant somatic
transformation should be considered. Analysis for iso-
chromosome 12 [i(12p)] might be helpful to confirm dif-
ferential diagnosis of recurrent GCC.28
Considering the remarkable diversity of treatment strategies
observed in this study, giving a clear treatment recom-
mendation for patients with CSI NS who experience relapse
after adjuvant BEP is difficult. Treatment at GCC expert
centers29 is strongly encouraged. Patients with a high like-
lihood of teratoma (negativemarkers, suggestive on imaging)
should undergo surgery first. If indeed pure teratoma is
found, the likelihood of cure with surgery alone is high.
According to existing guidelines, patients with late relapses
. 2 years might also be candidates for upfront surgery.
They subsequently should be treated according to the
histology found.
All other patients with a relapse after adjuvant BEP for CSI
NS should be treated primarily with chemotherapy
according to IGCCCG stage, keeping in mind that they may
have a slightly worse prognosis and higher risk of additional
relapse compared with patients who have de-novo meta-
static disease. Bearing in mind the cumulative dose of
bleomycin, including adjuvant treatment, and the potential
of lung toxicity, giving three to four cycles of a three-drug
regimen with replacement of bleomycin by another drug,
such as ifosfamide, might be considered for these patients.
Also, lowering the threshold for postchemotherapy retro-
peritoneal lymph node dissection should be considered,
even if complete response after such chemotherapy is
achieved.
In conclusion, this study was not intended to and cannot
solve the ongoing debate on the optimal choice of man-
agement for CSI NS. However, it adds information to the
rare clinical situation of relapses after adjuvant BEP for CSI
NS for which no comprehensive data were available so far.
We think that this new knowledge should be included in the
discussion with patients, carefully weighing all advantages
and disadvantages of the different management strategies
for CSI NS.
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Paris, France
7University Campus Bio-Medico, Rome, Italy
8F Hoffmann-La Roche Ltd, Basel, Switzerland
9Indiana University School of Medicine, Melvin and Bren Simon Cancer
Center, Indianapolis, IN
10Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
11Abteilung für Onkologie, Universitätsklinik für Innere Medizin,
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